Veritone to Hold Second Quarter 2025 Results Conference Call on August 7th
Veritone will hold a conference call on Thursday, August 7, 2025, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time), to discuss its results for the second quarter 2025, provide an update on the business and conduct a question-and-answer session.
To participate, please join the conference call or live audio webcast links or use the following dial-in numbers and ask to be connected to the Veritone earnings conference call. To avoid any delays, please join at least fifteen minutes prior to the start of the call.
Conference Call
Live Audio Webcast
Domestic Call Number: (844) 750-4897
International Call Number: (412) 317-5293
About Veritone
Veritone (NASDAQ: VERI) builds human-centered enterprise AI solutions. Serving customers in the media, entertainment, public sector and talent acquisition industries, Veritone's software and services empower individuals at the world's largest and most recognizable brands to run more efficiently, accelerate decision making and increase profitability. Veritone's leading enterprise AI platform, aiWARE™, orchestrates an ever-growing ecosystem of machine learning models, transforming data sources into actionable intelligence. By blending human expertise with AI technology, Veritone advances human potential to help organizations solve problems and achieve more than ever before, enhancing lives everywhere. To learn more, visit Veritone.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
8 minutes ago
- Cision Canada
Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction
VANCOUVER, BC, Aug. 12, 2025 /CNW/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an investment standpoint, the opportunity is enormous, with the market paying closer attention to AI roll outs and the developers behind them, including Avant Technologies, Inc. (OTCQB: AVAI), RadNet, Inc. (NASDAQ: RDNT), Clover Health Investments, Corp. (NASDAQ: CLOV), Tevogen Bio Holdings Inc. (NASDAQ: TVGN), and Butterfly Network, Inc. (NYSE: BFLY). Accenture projects AI could unlock $461 billion in healthcare value by 2035, but success requires platforms that deliver reliable results in critical diagnostics where mistakes prove dangerous. Several innovators are developing advanced systems to capture this opportunity across patient screening and drug discovery. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have accelerated their FDA approval timeline for Vision AI, an AI-powered diagnostic tool that can detect diabetic retinopathy in minutes without requiring an eye specialist on-site. The companies have accelerated their timeline by finalizing an enhanced patient recruitment strategy targeting approximately 1,000 multiethnic patients across 8-10 U.S. clinical sites. Ainnova will collaborate directly with Fortrea, a globally recognized contract research organization specializing in ophthalmology studies, to recruit patients primarily from community clinics and primary care facilities. This approach captures real-world data that reflects the diverse population affected by diabetic retinopathy while positioning Vision AI for broader commercial adoption. "By focusing on community clinics and targeting a multiethnic group of around 1,000 diabetic patients, we aim to ensure that our study accurately represents the diverse population affected by diabetic retinopathy," said Vinicio Vargas, CEO at Ainnova and Board member of Ai-nova Acquisition Corp. (AAC). "Working with Fortrea, an expert CRO in ophthalmology, allows us to confidently navigate this process with a partner that shares our commitment to quality and efficiency. We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval and making our Vision AI platform a crucial tool in early disease detection." This recruitment breakthrough builds on decisive regulatory progress following Ainnova's mid-July pre-submission meeting with the FDA, where the agency delivered clear guidance on study design and compliance requirements. The refined clinical trial protocol, which addresses all FDA comments, has been presented to Fortrea for final review and will set the stage for a formal U.S. study that supports FDA 510(k) clearance to market Vision AI domestically. Beyond regulatory advancement, Vision AI is gaining commercial momentum across multiple fronts. Vargas recently showcased the platform at Roche's"Macular Spectacular" conference in Colombia, highlighting breakthrough results from a Q4 2024 pilot with Roche and Salud 360 that positions Vision AI for expansion across the U.S., Canada, and Europe. The technology has already gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, delivering walk-in screenings with real-time AI results and eliminating the need for onsite ophthalmologists. This proven pharmacy model is attracting attention from insurers and life sciences partners who recognize Vision AI's potential to transform preventive care delivery. The platform's cost-effective approach addresses critical gaps in diabetic eye care while creating new revenue streams for retail healthcare providers. Vision AI's success positions Ainnova to dominate broader disease detection markets. The company's expanding roadmap includes cloud-connected retinal cameras for rural clinics and revolutionary modules targeting Alzheimer's, cardiovascular conditions, and other chronic diseases through advanced retinal and blood biomarker analysis. With diabetic retinopathy affecting 9.6 million Americans and representing a US$3.25 billion U.S. market projected to nearly double to US$6.1 billion by 2033, Avant maintains worldwide licensing rights to Ainnova's platform through AAC. This positions U.S. market entry as a transformative commercial inflection point. Avant continues evaluating a strategic acquisition of Ainnova Tech under a previously announced non-binding LOI, potentially consolidating breakthrough AI healthcare technologies and proven leadership under a single public platform. The company has also signaled plans for a dedicated therapeutic-focused spinout, creating multiple pathways to capture the expanding AI-driven healthcare transformation. RadNet, Inc. (NASDAQ: RDNT), through its wholly-owned subsidiary DeepHealth Inc., received FDA 510(k) clearance for TechLive™, a remote scanning solution that enables centralized operation of MR, CT, PET/CT, and ultrasound procedures across multiple locations simultaneously. The technology addresses critical radiology technologist shortages by allowing expert staff to remotely guide complex procedures, with pilot deployments showing a 42% decrease in MRI room closure hours. "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries." RadNet has already connected over 300 imaging systems with TechLive™, positioning the company to expand operational efficiency while improving patient access to advanced diagnostic procedures. Clover Health Investments, Corp. (NASDAQ: CLOV), through its wholly-owned subsidiary Counterpart Health, released clinical data showing its AI-powered Counterpart Assistant technology correlates with significantly improved COPD patient outcomes, including 15% fewer hospitalizations and 18% lower 30-day readmissions. "This whitepaper shows how translating raw data into real-time clinical insight can transform care," said Conrad Wai, CEO of Counterpart Health. "By equipping physicians with timely, meaningful guidance, Counterpart Assistant helps deliver better outcomes for patients and reduce costs." The platform synthesizes over 100 real-time data streams to provide actionable recommendations within clinical workflows, with COPD patients under Counterpart-enabled primary care physicians showing 75% higher diagnosis rates and 18% more specialty care visits. This marks Counterpart's fifth published study demonstrating clinical impact across chronic diseases including diabetes, heart failure, and kidney disease management. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has evolved from a biotechnology company into a dual-platform enterprise expanding into artificial intelligence through while maintaining 74% insider ownership. The company successfully launched its AI-driven PredicTcell™ platform with strategic partnerships including Microsoft and Databricks, significantly enhancing drug target discovery efficiency with potential savings of billions in development costs. CEO Ryan Saadi affirmed the company's strong capital position and growth trajectory, highlighting progress from clinical validation of its ExacTcell™ platform to establishing manufacturing capabilities and robust intellectual property portfolios. "Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency," wrote Saadi in a CEO letter. "In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership." Butterfly Network, Inc. (NYSE: BFLY) advanced AI-powered cardiac screening through new research demonstrating machine learning models can achieve 94% accuracy in detecting aortic stenosis using handheld ultrasound devices. "This research shows a promising path forward where lower-level providers, not just cardiologists or trained sonographers, could screen for aortic stenosis using AI-assisted handheld ultrasound," said Dr. John Martin, co-author of the study and Butterfly's Chief Medical Officer Emeritus. "This opens the door to early detection in a wide variety of care venues including primary care offices, long term care facilities, urgent care facilities and even in the home." The study, published in European Heart Journal, validates the potential for lower-level providers to screen for this life-threatening condition that affects over 13% of Americans over 75 and often goes undiagnosed until advanced stages. Butterfly also released new Aorta Exam training protocols on its ScanLab™ platform, combining AI-assisted diagnostics with educational tools to democratize access to critical cardiovascular screening capabilities. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Globe and Mail
8 minutes ago
- Globe and Mail
IPA Capital Markets Arranges $76M Financing for Los Angeles County Multifamily Development
IPA Capital Markets, a division of Marcus & Millichap (NYSE:MMI) specializing in capital markets services for major private and institutional clients, announced it has arranged $76 million in construction financing for The Monroe, a Class A mixed-use multifamily and retail development at 127 West Pomona Ave. in Monrovia, California. The transit-oriented project is under construction and scheduled for completion in September 2025. Stefen Chraghchian, senior director in IPA Capital Markets' Encino office, secured the financing with Affinius Capital on behalf of Adept Urban Development. 'We worked diligently to provide our client with competitive and flexible loan terms supporting a streamlined construction completion and lease-up process for The Monroe,' said Chraghchian. 'This included increased funding for lease-up soft costs, a spread decrease upon achieving 25% occupancy, and an earnout advance at stabilization.' The Monroe will feature 232 residential apartments and approximately 7,050 square feet of ground floor commercial space. Apartments will range from studios to three-bedroom units, and 25 of the units will be designated affordable for very low- and moderate-income households. The property will have 302 residential parking spaces and 85 public parking spaces. Additional amenities will include a gym, swimming pool, spa, clubhouse, barbecue area, rooftop patio and conference/meeting rooms. 'This project will deliver quality housing and retail in a fast-growing rental market, addressing demand while enhancing needed neighborhood amenities,' added Chraghchian. About IPA Capital Markets IPA Capital Markets is a division of Marcus & Millichap (NYSE: MMI). IPA Capital Markets provides major private and institutional clients with commercial real estate capital markets financing solutions, including debt, mezzanine financing, preferred and joint venture equity, and sponsor equity. For more information, please visit Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. Marcus & Millichap closed 7,836 transactions with a sales volume of approximately $49.6 billion in 2024. The company had 1,712 investment sales and financing professionals in more than 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate at year end. For additional information, please visit .
Globe and Mail
8 minutes ago
- Globe and Mail
Xcel Brands to Host Second Quarter 2025 Earnings Call on August 14, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Xcel Brands, Inc. (NASDAQ: XELB) ('Xcel' or the 'Company'), today announced that it will report its second quarter 2025 financial results on August 14, 2025. The Company will hold a conference call with the investment community on August 14, 2025, at 9:00 a.m. ET. A webcast of the conference call will be available live on the Investor Relations section of Xcel's website at or directly at Interested parties unable to access the conference call via the webcast may dial 800-715-9871 or 646-307-1963 and use the Conference ID 9043618. A replay of the webcast will be available on Xcel's website. About Xcel Brands Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the co-branded collaboration brands TowerHill by Christie Brinkley, LB70 by Lloyd Boston, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford, and a brand in development with Coco Rocha and also holds noncontrolling interests or long-term license agreements in the Isaac Mizrahi brand, Orme Live, and Mesa Mia Live by Jenny Martinez. Xcel also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers shop. The company's brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone, and over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches in excess of 43 million social media followers with broadcast reach into 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit
